Strontium Ranelate reduces the number of radiological or radioclinical progressors in patients with primary knee osteoarthritis

Reginster, J. Y., Chapurlat, R., Christiansen, C., Genant, H., Bellamy, N., Bensen, W., Navarro, F., Badurski, J., Nasonov, E., Chevalier X., Sambrook, P. N., Spector, T. and Cooper, C. (2012). Strontium Ranelate reduces the number of radiological or radioclinical progressors in patients with primary knee osteoarthritis. In: Kanis, J.A. and Lindsay, R., IOF-ECCEO12 European Congress on Osteoporosis and Osteoarthritis, Bordeaux, France, (S366-S367). 21-24 March 2012. doi:10.1007/s00198-012-1928-7


Author Reginster, J. Y.
Chapurlat, R.
Christiansen, C.
Genant, H.
Bellamy, N.
Bensen, W.
Navarro, F.
Badurski, J.
Nasonov, E.
Chevalier X.
Sambrook, P. N.
Spector, T.
Cooper, C.
Title of paper Strontium Ranelate reduces the number of radiological or radioclinical progressors in patients with primary knee osteoarthritis
Conference name IOF-ECCEO12 European Congress on Osteoporosis and Osteoarthritis
Conference location Bordeaux, France
Conference dates 21-24 March 2012
Journal name Osteoporosis International   Check publisher's open access policy
Place of Publication Surrey, United Kingdom
Publisher Springer
Publication Year 2012
Sub-type Published abstract
DOI 10.1007/s00198-012-1928-7
ISSN 0937-941X
1433-2965
Editor Kanis, J.A.
Lindsay, R.
Volume 23
Issue Suppl 2
Start page S366
End page S367
Total pages 2
Language eng
Formatted Abstract/Summary
Objective(s): Strontium ranelate (SrRan) has demonstrated a structure-modifying activity associated with symptoms improvement in patients with knee OA in a large, randomised, placebo-controlled, double-blind phase-III 3-year study. Patients with joint space width narrowing (JSN) of 0.5 mm over 3 years have a higher risk of undergoing any OA-related lower limb surgery (1). Both radiological progression and lack of improvement in symptoms have been considered by the GREES as clinically relevant endpoints (2). The objective of this planned analysis was to describe the efficacy of SrRan on radiological and radioclinical progression.
Material and Methods: 1683 patients with symptomatic primary knee OA (ACR criteria) were included and randomly assigned to SrRan 1 g, 2 g or placebo for 3 years. Radiological progressors between baseline and last observation (defined as patients with a JSN≥0.5 mm) and radioclinical progressors (defined as patients with a JSN≥0.5 mm and with a lack of clinical improvement in symptoms (e.g., ≤20% improvement in WOMAC pain subscore) were compared across groups in the ITT using a chi-square test.
Results: Radiological progressors between baseline and last observation were  significantly less frequent in the SrRan groups than in the placebo group: 22.3% (p<0.001), 25.6% (p=0.012) in the SrRan 1 g and 2 g groups, respectively, compared to the placebo group (33.1%). The RRR (and NNT) compared to placebo were 32.7% (NNT=10) and 22.7% (NNT=14) in the 1 g and 2 g group, respectively. Similar results were observed when considering patients with both significant radiological progression and lack of symptom improvement. Less radioclinical progressors were observed in the SrRan 1 g and 2 g group than in the placebo group (7.7%, p=0.049; 6.5%, p=0.008 vs. 11.6%, respectively). The RRR (and NNT) compared to placebo were 34.0% (NNT=26) and 44.1% (NNT=20) in the 1 g and 2 g group, respectively.
Conclusion(s): Strontium ranelate 1 and 2 g/day reduce the number of knee OA  patients with a radiological and radioclinical progression. This shows that SrRan could have a positive effect in decreasing lower limb surgery.
Q-Index Code EX
Q-Index Status Provisional Code
Institutional Status UQ

Document type: Conference Paper
Collection: School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: Google Scholar Search Google Scholar
Created: Fri, 22 Jun 2012, 15:16:06 EST by Chesne McGrath on behalf of Medicine - Royal Brisbane and Women's Hospital